menu
    • menu

    Company profile for Tenaya Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tenaya’s approach involves in vivo reprogramming of resident cardiac fibroblasts into cardiomyocytes. Tenaya uses novel AAV vectors to introduce proprietary combinations of known transcription factors – genes that control cellular identity and function – to convert cardiac fibroblasts into cardiomyocytes. This can help repair the heart, reduce the scar area, and improve heart function.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tenaya TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    171 Oyster Point Blvd suite 500, South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tenayatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tenaya-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tenaya Therapeutics Announces Pricing Of Public Offering
    Tenaya Therapeutics Announces Pricing Of Public Offering

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204434/0/en/Tenaya-Therapeutics-Announces-Pricing-of-Public-Offering.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Tenaya Therapeutics Announces Proposed Public Offering
    Tenaya Therapeutics Announces Proposed Public Offering

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204290/0/en/Tenaya-Therapeutics-Announces-Proposed-Public-Offering.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Tenaya Resolves Clinical Hold On Mypeak-1 Gene Therapy Trial
    Tenaya Resolves Clinical Hold On Mypeak-1 Gene Therapy Trial

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204289/0/en/Tenaya-Therapeutics-Announces-Rapid-Resolution-and-Lifting-of-Clinical-Hold-for-MyPEAK-1-Phase-1b-2a-Clinical-Trial-of-TN-201-Gene-Therapy.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Tenaya Therapeutics Reveals Positive Interim Results
    Tenaya Therapeutics Reveals Positive Interim Results

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204284/0/en/Tenaya-Therapeutics-Reports-Positive-Interim-Data-from-Cohort-1-of-RIDGE-1-Phase-1b-2-Clinical-Trial-of-TN-401-Gene-Therapy-for-Adults-with-PKP2-associated-ARVC.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    FDA Puts Tenaya Heart Disease Gene Therapy Trial On Hold
    FDA Puts Tenaya Heart Disease Gene Therapy Trial On Hold

    10 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fda-puts-tenaya-heart-disease-gene-therapy-clinical-trial-hold

    FIERCE BIOTECH
    10 Nov 2025
    Share Share
    Tenaya Therapeutics Reports Q3 2025 Financials & Business Update
    Tenaya Therapeutics Reports Q3 2025 Financials & Business Update

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184369/0/en/Tenaya-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search